SARS-CoV-2 mRNA Vaccines Sensitize Tumours to Immune Checkpoint Blockade
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade, according to research published in Nature.
-
Key Clinical Takeaways:
- Receipt of a SARS-CoV-2 mRNA vaccine within 100 days of immune checkpoint inhibitor initiation is associated with improved median and three-year overall survival in multiple large retrospective cohorts.
- The therapeutic benefit requires a surge in type-I interferon that enhances antigen-presenting cell priming of T cells in lymphoid organs.
- Tumour cells subvert these responses by increasing programmed death-ligand 1 expression, requiring co-administration of inhibitors to sustain T cell activity.
SARS-CoV-2 mRNA vaccines boost interferon to prime CD8+ T cells
Immune checkpoint inhibitors extend survival in many patients with cancer but remain ineffective in patients without pre-existing immunity. Personalized mRNA cancer vaccines sensitize tumours to these inhibitors by directing immune attacks against preselected antigens. However, personalized vaccines face limitations due to complex and time-intensive manufacturing processes.
Preclinical models evaluated in the study demonstrate that SARS-CoV-2 mRNA vaccines lead to a substantial increase in type I interferon. This enables innate immune cells to prime CD8+ T cells targeting tumour-associated antigens. Concomitant treatment with immune checkpoint inhibitors is required for maximal efficacy in immunologically cold tumours, which respond by increasing PD-L1 expression.
Clinical findings across retrospective cohorts
Patients receiving SARS-CoV-2 mRNA vaccines within 100 days of starting therapy show higher median and three-year overall survival rates in several large retrospective cohorts. This benefit remains consistent among patients presenting with immunologically cold tumours.
Poor responses to checkpoint inhibitors are typically attributed to immunosuppressive tumour microenvironments characterized by tolerogenic dendritic cells, myeloid suppressor cells, and regulatory T cells. Clinically available mRNA vaccines targeting non-tumour-related antigens function as potent immune modulators capable of resetting this cycle. Systemic administration of highly immunogenic mRNA nanoparticles induces a viraemia-like cytokine and chemokine response that alters the systemic and intratumoural immune milieu.
COVID-19 mRNA vaccines induce cytokines enabling synergy with checkpoint blockade
While personalized mRNA vaccines undergo clinical evaluation in trials such as NCT04573140, COVID-19 mRNA vaccines induce strong cytokine secretion. Multiple case reports previously documented patients whose tumours spontaneously resolved after receiving COVID-19 mRNA vaccines. The current findings demonstrate that the innate response to spike mRNA vaccination primes adaptive immunity for synergy with checkpoint blockade in patients with non-small cell lung cancer and melanoma.
Additional findings and author affiliations
The research evaluated the impact of COVID-19 mRNA vaccines on immune therapy in non-small cell lung cancer and melanoma, revealing analogous human response correlates such as heightened IFNα production and innate and adaptive immune activation alongside tumour PD-L1 expression increases.
The work involved multiple institutional contributors spanning departments of radiation oncology, neurosurgery, thoracic and head and neck medical oncology, and biostatistics at organizations including The University of Texas MD Anderson Cancer Center, the University of Florida McKnight Brain Institute, McGovern Medical School, Baylor College of Medicine, Stanford University, Scripps Health, and the University of North Carolina.
Nature, the British weekly scientific journal that published the study, was founded in the autumn of 1869 by Norman Lockyer and Alexander MacMillan as a public forum for scientific innovations. It operates editorial offices in London, the United States, continental Europe, and Asia under Springer Nature and, as of 2012, claimed an online readership of about three million unique readers per month. Fewer than 8% of submitted papers are accepted for publication.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.